Quick Answer
Beam Therapeutics Inc. reported Operating Income of -$383.69 million for fiscal year 2025.
Beam Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$383.69M | +7.7% |
| 2024 | -$415.57M | -135.5% |
| 2023 | -$176.49M | +47.9% |
| 2022 | -$338.48M | +13.8% |
| 2021 | -$392.46M | -195.6% |
| 2020 | -$132.76M | -76.7% |
| 2019 | -$75.15M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$126.81M | -19.1% | -5.5% |
| June 30, 2025 | -$120.15M | -14.5% | -0.7% |
| March 31, 2025 | -$119.29M | -14.6% | -12.0% |
| September 30, 2024 | -$106.50M | +1.6% | -1.5% |
| June 30, 2024 | -$104.89M | -2.7% | -0.7% |
| March 31, 2024 | -$104.13M | -5.3% | +3.8% |
| September 30, 2023 | -$108.27M | -18.6% | -6.0% |
| June 30, 2023 | -$102.15M | -24.6% | -3.3% |
- Beam Therapeutics Inc. showed an increase of +7.7% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Beam Therapeutics Inc.’s operating income has declined by 410.5% (from -$75.15 million to -$383.69 million).
- The most recent figure is from Beam Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: